Literature DB >> 17567701

An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys.

Minetaro Arita1, Noriyo Nagata, Naoko Iwata, Yasushi Ami, Yuriko Suzaki, Katsumi Mizuta, Takuya Iwasaki, Tetsutaro Sata, Takaji Wakita, Hiroyuki Shimizu.   

Abstract

Enterovirus 71 (EV71) is a causative agent of hand, foot, and mouth disease and is also sometimes associated with serious neurological disorders. In this study, we characterized the antigenicity and tissue specificity of an attenuated strain of EV71 [EV71(S1-3')], which belongs to genotype A, in a monkey infection model. Three cynomolgus monkeys were inoculated with EV71(S1-3'), followed by lethal challenge with the parental virulent strain EV71(BrCr-TR) via an intravenous route on day 45 postinoculation of EV71(S1-3'). Monkeys inoculated with EV71(S1-3') showed a mild neurological symptom (tremor) but survived lethal challenge by virulent EV71(BrCr-TR) without exacerbation of the symptom. The immunized monkey sera showed a broad spectrum of neutralizing activity against different genotypes of EV71, including genotypes A, B1, B4, C2, and C4. For the strains examined, the sera showed the highest neutralization activity against the homotype (genotype A) and the lowest neutralization activity against genotype C2. The order of decreasing neutralization activity of sera was as follows: A > B1 > C4 > B4 > C2. To examine the tissue specificity of EV71(S1-3'), two monkeys were intravenously inoculated with EV71(S1-3'), followed by examination of virus distribution in the central nervous system (CNS) and extraneural tissues. In the CNS, EV71(S1-3') was isolated only from the spinal cord. These results indicate that EV71(S1-3') acts as an effective antigen, although this attenuated strain was still neurotropic when inoculated via the intravenous route.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17567701      PMCID: PMC1951441          DOI: 10.1128/JVI.02856-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Rapid serological diagnosis of enterovirus 71 infection by IgM ELISA.

Authors:  Yoshio Tano; Hiroyuki Shimizu; Masashi Shiomi; Takashi Nakano; Tatsuo Miyamura
Journal:  Jpn J Infect Dis       Date:  2002-08       Impact factor: 1.362

2.  Pathogenesis of poliomyelitis; reappraisal in the light of new data.

Authors:  A B SABIN
Journal:  Science       Date:  1956-06-29       Impact factor: 47.728

3.  Mutation of a single conserved nucleotide between the cloverleaf and internal ribosome entry site attenuates poliovirus neurovirulence.

Authors:  Nidia De Jesus; David Franco; Aniko Paul; Eckard Wimmer; Jeronimo Cello
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

4.  Temperature-sensitive mutants of enterovirus 71 show attenuation in cynomolgus monkeys.

Authors:  Minetaro Arita; Hiroyuki Shimizu; Noriyo Nagata; Yasushi Ami; Yuriko Suzaki; Tetsutaro Sata; Takuya Iwasaki; Tatsuo Miyamura
Journal:  J Gen Virol       Date:  2005-05       Impact factor: 3.891

5.  Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease.

Authors:  L Y Chang; T Y Lin; K H Hsu; Y C Huang; K L Lin; C Hsueh; S R Shih; H C Ning; M S Hwang; H S Wang; C Y Lee
Journal:  Lancet       Date:  1999-11-13       Impact factor: 79.321

6.  Pathogenicity of a poliomyelitis-like disease in monkeys infected orally with enterovirus 71: a model for human infection.

Authors:  I Hashimoto; A Hagiwara
Journal:  Neuropathol Appl Neurobiol       Date:  1982 Mar-Apr       Impact factor: 8.090

7.  A mutation in the RNA polymerase of poliovirus type 1 contributes to attenuation in mice.

Authors:  M Tardy-Panit; B Blondel; A Martin; F Tekaia; F Horaud; F Delpeyroux
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

8.  Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema.

Authors:  Shih-Min Wang; Huan-Yao Lei; Kao-Jean Huang; Jing-Ming Wu; Jen-Ren Wang; Chun-Keung Yu; Ih-Jen Su; Ching-Chuan Liu
Journal:  J Infect Dis       Date:  2003-07-23       Impact factor: 5.226

9.  Characterization of in vitro and in vivo phenotypes of poliovirus type 1 mutants with reduced viral protein synthesis activity.

Authors:  Minetaro Arita; Hiroyuki Shimizu; Tatsuo Miyamura
Journal:  J Gen Virol       Date:  2004-07       Impact factor: 3.891

10.  Enterovirus 71 outbreaks, Taiwan: occurrence and recognition.

Authors:  Tzou-Yien Lin; Shiing-Jer Twu; Mei-Shang Ho; Luan-Yin Chang; Chin-Yun Lee
Journal:  Emerg Infect Dis       Date:  2003-03       Impact factor: 6.883

View more
  61 in total

1.  Reemergence of enterovirus 71 in 2008 in taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008.

Authors:  Sheng-Wen Huang; Yun-Wei Hsu; Derek J Smith; David Kiang; Huey-Pin Tsai; Kuei-Hsiang Lin; Shih-Min Wang; Ching-Chung Liu; Ih-Jen Su; Jen-Ren Wang
Journal:  J Clin Microbiol       Date:  2009-09-23       Impact factor: 5.948

2.  VP1 Amino Acid Residue 145 of Enterovirus 71 Is a Key Residue for Its Receptor Attachment and Resistance to Neutralizing Antibody during Cynomolgus Monkey Infection.

Authors:  Ken Fujii; Yui Sudaka; Ayako Takashino; Kyousuke Kobayashi; Chikako Kataoka; Tadaki Suzuki; Naoko Iwata-Yoshikawa; Osamu Kotani; Yasushi Ami; Hiroyuki Shimizu; Noriyo Nagata; Katsumi Mizuta; Yoko Matsuzaki; Satoshi Koike
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

3.  A Novel Murine Model Expressing a Chimeric mSCARB2/hSCARB2 Receptor Is Highly Susceptible to Oral Infection with Clinical Isolates of Enterovirus 71.

Authors:  Cheng-Hung Yang; Chung-Tiang Liang; Si-Tse Jiang; Kuan-Hsing Chen; Chun-Chiao Yang; Mei-Ling Cheng; Hung-Yao Ho
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

4.  Molecular determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B 2.

Authors:  Pan Chen; Zilin Song; Yonghe Qi; Xiaofeng Feng; Naiqing Xu; Yinyan Sun; Xing Wu; Xin Yao; Qunyin Mao; Xiuling Li; Wenjuan Dong; Xiaobo Wan; Niu Huang; Xinliang Shen; Zhenglun Liang; Wenhui Li
Journal:  J Biol Chem       Date:  2012-01-04       Impact factor: 5.157

5.  Cryo-electron microscopy study of insect cell-expressed enterovirus 71 and coxsackievirus a16 virus-like particles provides a structural basis for vaccine development.

Authors:  Minqing Gong; Hongtao Zhu; Jun Zhou; Chunting Yang; Jing Feng; Xiaojun Huang; Gang Ji; Honglin Xu; Ping Zhu
Journal:  J Virol       Date:  2014-03-26       Impact factor: 5.103

Review 6.  Therapeutic and prevention strategies against human enterovirus 71 infection.

Authors:  Chee Choy Kok
Journal:  World J Virol       Date:  2015-05-12

7.  Rational design of thermostable vaccines by engineered peptide-induced virus self-biomineralization under physiological conditions.

Authors:  Guangchuan Wang; Rui-Yuan Cao; Rong Chen; Lijuan Mo; Jian-Feng Han; Xiaoyu Wang; Xurong Xu; Tao Jiang; Yong-Qiang Deng; Ke Lyu; Shun-Ya Zhu; E-De Qin; Ruikang Tang; Cheng-Feng Qin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-15       Impact factor: 11.205

8.  Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene.

Authors:  Kok Keng Tee; Tommy Tsan-Yuk Lam; Yoke Fun Chan; Jon M Bible; Adeeba Kamarulzaman; C Y William Tong; Yutaka Takebe; Oliver G Pybus
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

Review 9.  Progress on the research and development of human enterovirus 71 (EV71) vaccines.

Authors:  Zhenglun Liang; Qunying Mao; Fan Gao; Junzhi Wang
Journal:  Front Med       Date:  2012-12-17       Impact factor: 4.592

10.  The cross-reactivity of the enterovirus 71 to human brain tissue and identification of the cross-reactivity related fragments.

Authors:  Chun Shi Jia; Jiang Ning Liu; Wan Bo Li; Chun Mei Ma; Shu Zhu Lin; Yi Hao; Xue Zhong Gao; Xiao Lin Liu; Yan Feng Xu; Lian Feng Zhang; Chuan Qin
Journal:  Virol J       Date:  2010-02-22       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.